Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights a significant performance disclosure period for listed companies, focusing on high-growth sectors such as gold and jewelry, cosmetics, and medical aesthetics, with a notable divergence in performance among consumer brands [4][25] - High-end domestic brands like Laopuhuangjin and Maogeping are showing strong growth, while brands that adapt to channel changes and possess differentiated product capabilities, such as Chaohongji and Shangmei, are also performing well [4][25] Summary by Sections Retail and Social Services Market Review - The retail and social services indices reported declines of 1.10% and 1.52% respectively during the week of March 23-27, 2026, ranking 19th and 24th among 31 primary industries [6][14] - The jewelry sector saw the highest weekly increase of 1.05%, while the hotel and restaurant sector led year-to-date performance with a 0.77% increase [18][20] Industry Dynamics - The report emphasizes the ongoing annual report disclosures from listed companies, with a focus on high-growth companies [25] - The gold and jewelry sector continues to show a trend towards high-end and fashionable products, with Laopuhuangjin and Chaohongji demonstrating exceptional performance [28][39] Investment Recommendations - Investment focus areas include: - Gold and jewelry brands with differentiated product capabilities, recommending Laopuhuangjin, Chaohongji, and Zhou Dafu [7][42] - Offline retail companies adapting to trends and AI-enabled cross-border e-commerce leaders, recommending Yonghui Supermarket and Jihong Co [7][39] - Cosmetics brands that meet emotional value and safety innovation, recommending Maogeping, Shangmei, and Beitaini [7][40] - Medical aesthetics firms with differentiated products and expanding chains, recommending Aimeike and Meilitiantian Medical Health [7][41] Company-Specific Insights - Laopuhuangjin reported a revenue of 27.303 billion yuan (+221.0%) and a net profit of 4.868 billion yuan (+230.5%) for FY2025, with expectations for continued growth in Q1 2026 [28][41] - Chaohongji achieved a revenue of 9.318 billion yuan (+43.0%) and a net profit of 497 million yuan (+156.7%) for FY2025, with rapid growth in its franchise business [45][46] - Maogeping's revenue reached 5.050 billion yuan (+30.0%) with a net profit of 1.205 billion yuan (+36.8%) for FY2025, showcasing strong performance in high-end channels [32][41] - Shangmei reported a revenue of 9.178 billion yuan (+35.1%) and a net profit of 1.103 billion yuan (+41.1%) for FY2025, with a focus on multi-category growth [32][41]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][11] Core Insights - The company reported a revenue increase of 30.0% year-on-year for 2025, reaching 5.05 billion yuan, and a net profit increase of 36.8%, amounting to 1.205 billion yuan. The brand's momentum continues to be strong, leading to an upward revision of profit forecasts for 2026-2028 [4][5] - The company expects net profits for 2026, 2027, and 2028 to be 1.587 billion, 1.978 billion, and 2.457 billion yuan respectively, with corresponding EPS of 3.24, 4.04, and 5.01 yuan. The current stock price corresponds to P/E ratios of 19.0, 15.2, and 12.2 for the respective years [4][7] Financial Performance - In 2025, the company's revenue from different segments was as follows: makeup 2.996 billion yuan (up 30.0%), skincare 1.873 billion yuan (up 31.1%), and training 147 million yuan (down 2.8%). The newly added fragrance segment generated 34 million yuan [5] - The online and offline channels generated revenues of 2.477 billion and 2.426 billion yuan respectively, with year-on-year growth of 38.8% and 24.5% [5] - The gross profit margin for 2025 was 84.2%, with slight decreases in various segments, while the overall expense ratios for sales and management showed a steady decline [5][7] Business Development - The company continues to strengthen its high-end positioning with successful product launches in the makeup and skincare segments, including significant sales from key products [6] - The company has expanded its presence in high-end retail locations and online platforms, achieving notable sales growth in e-commerce channels [6]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][11] Core Insights - The company reported a revenue increase of 30.0% year-on-year for 2025, reaching 5.05 billion yuan, and a net profit increase of 36.8%, amounting to 1.205 billion yuan. The brand's momentum continues to be strong, leading to an upward revision of profit forecasts for 2026-2028 [4][5] - The company expects net profits for 2026, 2027, and 2028 to be 1.587 billion, 1.978 billion, and 2.457 billion yuan respectively, with corresponding EPS of 3.24, 4.04, and 5.01 yuan. The current stock price corresponds to P/E ratios of 19.0, 15.2, and 12.2 for the respective years [4][7] Financial Performance - In 2025, the revenue breakdown by business segment was as follows: makeup 2.996 billion yuan (up 30.0%), skincare 1.873 billion yuan (up 31.1%), and makeup training 147 million yuan (down 2.8%). The newly added fragrance segment generated 34 million yuan [5] - Revenue from online and offline channels reached 2.477 billion and 2.426 billion yuan respectively, with year-on-year growth of 38.8% and 24.5% [5] - The gross margin for 2025 was 84.2%, with slight decreases in various segments, while the overall expense ratios for sales and management decreased to 48.3% and 5.3% respectively [5] Business Development - The company has solidified its leading position in high-end domestic makeup, with significant sales from key products such as the small gold fan powder and caviar cushion, each exceeding 300 million yuan. The skincare segment also saw strong performance with flagship products achieving over 1 billion yuan in retail sales [6] - The company is expanding its high-end channel presence and has opened new stores in prestigious locations, enhancing its brand positioning. The online sales channels are also performing well, with significant growth expected to continue [6]

Core Viewpoint - The founding family of Maogeping Cosmetics plans to collectively reduce their shareholding after the stock price has doubled since its listing, indicating a normal financial arrangement rather than a lack of confidence in the company's future [1][2]. Group 1: Shareholding Reduction - On January 6, Maogeping announced that its controlling shareholders intend to reduce their holdings by up to 17.2 million H shares, representing 3.51% of the total issued shares, primarily through block trades within six months [1]. - The planned cash-out amount is approximately HKD 1.41 billion, based on the closing price of HKD 82 per share on January 6 [2]. - Despite the reduction announcement, the stock price increased by over 8% on the day of the announcement, closing at HKD 87.95, reflecting a market reaction that is considered rational [2]. Group 2: Company Performance - Maogeping has shown strong financial growth, with a revenue of CNY 2.588 billion for the first half of 2025, a year-on-year increase of 31.3%, and a net profit of CNY 670 million, up 36.1% [4]. - For the full year of 2024, the company reported revenues of CNY 3.885 billion, a 34.61% increase, and a net profit of CNY 881 million, growing by 32.8% [4]. - The company's gross margin has consistently remained above 80%, with figures of 83.4%, 83.8%, 84.8%, 84.4%, and 84.2% from 2021 to the first half of 2025 [4]. Group 3: Strategic Initiatives - The company is actively expanding its product offerings and distribution channels, including entering high-end department stores and enhancing its online presence through platforms like Tmall and Douyin [5]. - A restricted stock incentive plan has been proposed to strengthen the long-term incentive mechanism for core employees, aligning their interests with those of shareholders [5]. - Analysts from Everbright Securities and Huayuan Securities express optimism about the company's high-end positioning and growth potential, forecasting net profits of CNY 1.21 billion, CNY 1.58 billion, and CNY 2.04 billion for 2025 to 2027 [5].